CYSM Showcases Exclusive Technology That Makes Its Body Shapers Different in Wake of Rise of Comfortable Shapewear
As comfortable shapewear is taking over the market, CYSM Shapers has proudly showcased the technology that makes its products stand out among the competitors.
"Body shapers are no longer these cumbersome, uncomfortable things that you only wear on a special night out and hope you can make it through the discomfort in one piece," a company representative stated. "We have been vocal proponents of daily shapewear for many years, and we put our work behind our stance."
It all starts with advanced shapewear engineering, the representative added, saying that all CYSM Premium Shapewear is certified under the OEKO-TEX Standard 100.
"That's a globally recognized testing and certification system for textiles. The certification process is rigorous, for sure, but it makes sure that our shapewear meets the highest standards for safety and quality. It shows our commitment to trustworthy shapewear that blends fashion with health for everyday needs."
Under this standard, CYSM is classified as Class II, meaning safe for prolonged skin contact but also well-suited for post-surgery recovery.
"It's interesting," the rep added. "Our journey started over 30 years ago and we were initially 100 percent focused on crafting shapewear post-surgery recovery. We never gave up on that, we just expanded."
However, the rep added that the BIO Therapy Technology played a pivotal role in transforming CYSM Shapers into full-on daily shapewear that is safe and comfortable to use throughout the day.
The way BIO Therapy works is that it infuses microcapsules with marine algae onto the skin. The microcapsules are released upon skin contact, and they help restore elasticity, firmness, and beauty of the skin. They also grant antibacterial protection through prevention of bacteria and fungal growth. This promotes healthy skin and positively affects post-surgery recovery.
Finally, the breathable fabric regulates the temperature and reduces moisture to keep the skin feeling fresh.
"It's not just your figure, it's about your comfort," the company rep added before showcasing the multi-layered construction of the CYSM fabric. It features a high-compression outer layer, medium compression in the inner layer, and soft fabric at the bottom to keep the skin fresh and irritation-free.
When it comes to the fabric quality, the team stated: "At CYSM Shapewear, we prioritize top-quality products made from the finest materials. Our fabric is soft, hypoallergenic, and prevents irritation, which makes it ideal for long-term wear."
The premium-tier materials used in CYSM Premium Shapers promote airflow and moisture control. They create a microclimate for all-day comfort and freshness. The material also maintains its compression and its shape after stretching to achieve an effective fit.
The shapers are made to withstand frequent washing without losing shape or compression.
The team added that their ultimate goal is for their customers to feel confident and not covered up. "Stop hiding your body with oversized clothes," they said. "CYSM's tummy control shapewear gently shapes with soft, high-quality fabrics and smart compression—so you can confidently show off your figure."
In terms of sizing, the company maintains an inclusive approach and offers sizes from S to 3XL. Compression levels also vary, and can be adjusted between Medium, Heavy, and Ultra control for the highest degree of compression and sculpting.
A satisfied customer named Alejandra wrote in her 5-star review of one of the best-selling CYSM shapers: "Great, well-made tummy control body shaper. The material is very high-end, great material. Overall, I highly recommend this product!"
Beyond traditional shapewear, CYSM also offers post-surgery products and waist trainers. The company's Waist Trainer lineup focuses on providing the same compression benefits while also boosting the wearer's physical performance for better workout results. The Trainers also improve posture for extra benefits.
More information about CYSM Shapers, the company's history, technology, and the full product lineup, can all be found on the official website.
Media Contact
Company Name: CYSM Shapers
Contact Person: CYSM Team
Email: Send Email
Phone: +13235861600
Address: 5807 Pacific Blvd
City: Huntington Park
State: CA 90255
Country: United States
Website: https://cysm.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
30 minutes ago
- National Post
Jordan Peterson taking time off to fight new health setback, according to his daughter
Canadian psychologist, best-selling author and media commentator Jordan Peterson is taking time off for medical reasons, according to his daughter. Article content 'JBP is taking some time off of everything,' wrote podcast host and CEO of Peterson Academy, Mikhaila Peterson, on her X account earlier this week. Article content Article content Hey guys, @jordanbpeterson is taking some time off of everything. He was diagnosed with CIRS (chronic inflammatory response syndrome) due to a genetic predisposition that causes the immune system to have an inability to identify and detoxify mold/bacteria in indoor air (the… — Mikhaila Peterson (@MikhailaFuller) August 13, 2025 Article content Article content She says her father, a sometimes columnist for National Post, has been diagnosed with a condition known as chronic inflammatory response syndrome, or CIRS, and that it results in an immune deficiency that inhibits identifying and detoxifying indoor mold and bacteria. Article content Article content 'Recently he was exposed to a particularly moldy environment while helping clean out my grandfather's house after he passed away which severely flared symptoms. … He's really been suffering from this badly since 2017 we just didn't know what it was called,' she wrote. Article content This is the latest health setback for Peterson, 62, who fought to beat a benzodiazepine addiction in 2019. Article content After Peterson's addiction struggles were revealed, he announced he had developed akathisia — a condition which can cause restlessness, mental distress and an inability to sit still. Article content However, his daughter said that isn't an aspect of the present setback. She wrote on X: 'To be crystal clear — this isn't about akathisia or medication. He's not on any medication. It's an immune system dysfunction.' Article content Article content Conservative Leader, Pierre Poilievre has wished Peterson well. In a post to X on Saturday, he wrote: 'Praying for a swift recovery,' adding, 'The world needs his prodigious mind and solid principles now more than ever.' Article content Praying for a swift recovery for my friend Dr. @jordanbpeterson. The world needs his prodigious mind and solid principles now more than ever. — Pierre Poilievre (@PierrePoilievre) August 15, 2025
Globe and Mail
5 hours ago
- Globe and Mail
2 Top Dividend Stocks to Buy on the Dip
Key Points Pfizer's pipeline in oncology, combined with its cost-cutting initiatives, could help it bounce back. Merck could move beyond Keytruda thanks to newer approvals and a novel formulation of the medicine. Both companies have increased their dividends at a decent rate over the past five years. 10 stocks we like better than Pfizer › Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back. Investors looking for companies that fit this profile should strongly consider Pfizer (NYSE: PFE) and Merck (NYSE: MRK). These two market leaders have lagged broader equities over the trailing-12-month period, but for those focused on the long game, they still look attractive. Here's the rundown. 1. Pfizer Over the past few years, Pfizer has dealt with worsening financial results and stiff competition for some products. It also faces the prospect of losing patent protection for others; these include Eliquis, an anticoagulant that is one of its top-selling drugs, and Xtandi, a cancer treatment. Both will lose their patents in the U.S. within the next few years. These challenges have led to terrible stock-market performance. However, the sell-off may have gone too far. At current levels, Pfizer's shares look attractive. One reason the company should bounce back and continue to deliver strong returns over the long run is its deep pipeline, particularly in oncology, one of the largest therapeutic areas in the industry. Pfizer currently has five blockbuster cancer medicines, and plans to raise that number to eight by 2030. Pfizer has exciting candidates in other areas as well, and in recent years has earned approval for several new products. Though these aren't yet meaningfully contributing to its top-line growth, they should do so eventually as they earn label expansion. The company's vaccine for respiratory syncytial virus (RSV), Abrysvo, generated $143 million in sales in the second quarter, which isn't bad for a product approved in 2023. It also recently earned a label expansion in Europe for adults age 18 to 59 (it was previously indicated for those 60 and older). Pfizer should make progress with Abrysvo and other newer launches. The company has also been reducing expenses. These initiatives were likely partly responsible for Pfizer's earnings beat during the second quarter. Management intends to achieve $4.5 billion in net cost savings this year and pursue further reductions in the years ahead, efforts that should help improve profitability. Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in the past five years. While the stock may take some time to recover, Pfizer could be an excellent long-term investment for income-seeking investors. 2. Merck Merck is facing several issues, none more important than increased competition for its best-selling drug, cancer medicine Keytruda, and an upcoming patent cliff in 2028 for the medicine. Also, the company's second-quarter results were not strong: Revenue declined by 2% year over year to $15.8 billion, while adjusted earnings per share declined by 7% to $2.13. However, there were some bright spots for the company. Most notably, Winrevair -- one of its newest launches, which earned approval last year -- reported sales of $336 million. Winrevair is a therapy for pulmonary arterial hypertension with a new mechanism of action. It should become a blockbuster relatively soon. Merck's business in animal health -- where it's one of the leaders -- also performed well, with sales from that segment rising by 11% year over year to $1.6 billion in the second quarter. Meanwhile, Merck has some exciting pipeline candidates that should help it overcome Keytruda-related challenges. One of them is a subcutaneous version of Keytruda, which has already aced phase 3 studies and will help extend the medicine's patent protection. Merck has also significantly improved its pipeline in recent years thanks to licensing agreements. Its candidates include promising cancer products and weight loss medicines. Just as Winrevair appears to be a major success, Merck is also likely to develop innovative therapies that will mitigate potential Keytruda-related revenue losses. So, despite recent setbacks, the business could bounce back given Merck's history of innovation. Turning to Merck's dividend program, the company now offers a forward yield of 4.1%, with its dividends increasing by 39% over the past five years. The stock remains a good pick for dividend seekers. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
CTV News
a day ago
- CTV News
Hundreds may have been exposed to rabies at bat-infested cabins in Grand Teton National Park
Health officials are working to alert hundreds of people in dozens of states and several countries who may have been exposed to rabies in bat-infested cabins in Wyoming's Grand Teton National Park over the past few months. As of Friday, none of the bats found in some of the eight linked cabins at Jackson Lake Lodge had tested positive for rabies. But the handful of dead bats found and sent to the Wyoming State Veterinary Laboratory in Laramie for testing were probably only a small sample of the likely dozens that colonized the attic above the row of cabins, Wyoming State Health Officer Dr. Alexia Harrist said. Other bats weren't killed but got shooed out through cabin doors and windows. Meanwhile, the vast majority never flapped down from the attic into living spaces. Health officials thus deemed it better safe than sorry to alert everybody who has stayed in the cabins recently that they might have been exposed by being bitten or scratched. Especially when people are sleeping, a bat bite or scratch can go unseen and unnoticed. 'What we're really concerned about is people who saw bats in their rooms and people who might have had direct contact with a bat,' Harrist said Friday. The cabins have been unoccupied, with no plans to reopen, since concessionaire Grand Teton Lodge Company discovered the bat problem July 27. Bats are a frequent vector of the rabies virus. Once symptoms occur — muscle aches, vomiting, itching, to name a few — rabies is almost always fatal in humans. The good news is a five-shot prophylactic regimen over a two-week period soon after exposure is highly effective in preventing illness, Harrist noted. The cabins opened for the summer season in May after being vacant over the winter. Based on the roughly 250 reservations through late July, health officials estimated that up to 500 people had stayed in the cabins. They were trying to reach people in 38 states and seven countries through those states' health agencies and, in the case of foreign visitors, the U.S. Centers for Disease Control and Prevention. Others who have not been alerted yet but stayed in cabins 516, 518, 520, 522, 524, 526, 528 and 530 this year should tell health officials or a doctor immediately, Harrist said. Health officials were recommending prophylactic shots for people who fit certain criteria, such as deep sleepers who found a bat in their room, and children too young to say that they had seen a bat. The Wyoming Department of Health had no ongoing concern about visitor safety at the Jackson Lake Lodge area. That includes a Federal Reserve economic policy symposium Aug. 21-23 that takes place at Jackson Lake Lodge every summer. 'The lodge company has done a fantastic job of doing their due diligence of making sure everyone that is coming in for that, and for all other visits this year, are going to be as safe as possible,' said Emily Curren, Wyoming's public health veterinarian. 'Three or four' dead bats from the cabins tested negative and one that was mangled did not have enough brain tissue to be testable, Curren said. All were brown bats, which come in two species: 'little' and 'big,' with the larger ones more than twice as big. Officials were unsure which species these were, but both are common in Wyoming. They typically live in colonies of 30 to 100 individuals, Curren said. 'That's a lot of bats that we cannot rule out a risk of rabies being in,' Curren said. 'There's no way for us to know for certain about every single bat that got into these rooms.' There are no plans to exterminate the bats, Grand Teton National Park spokesperson Emily Davis said. Devices fitted to the building were keeping the bats from getting back in after flying out in pursuit of insects to eat, they said. Sejal Govindarao And Mead Gruver (), The Associated Press
